Compare First Trust NASDAQ Smart Grid ETF (GRID) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Smart Grid ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? First Trust NASDAQ Smart Grid ETF trades at $173.79 (market cap $12.09B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: First Trust NASDAQ Smart Grid ETF is far larger — about 2.5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ Smart Grid ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Smart Grid ETF for 14 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GRID | TVTX | |
|---|---|---|
Market Cap | $12.09B | $4.88B |
Volume | 561,107 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $199.80 | $67.52 |
52-Week Low | $146.51 | $26.79 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRID trades at $179.25, up 0.31% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock is positioned in the smart grid infrastructure sector, benefiting from AI-driven power buildout investments. Recent news highlights its exposure to infrastructure modernization and AI energy demand, though key financial ratios are not disclosed in the provided data.
Outlook is mixed: technicals suggest caution, but thematic tailwinds from AI infrastructure spending offer growth potential. Risks include sector competition and execution challenges. Investors should weigh near-term technical weakness against long-term infrastructure investment trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Trust NASDAQ Smart Grid ETF
First Trust NASDAQ Smart Grid Infrastructure ETF seeks to track companies involved in smart grid and electricity infrastructure. Its holdings include businesses related to power networks, energy management, and grid technologies.
Read more on GRID →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
